Important update: Healthcare facilities
CDC has updated select ways to operate healthcare systems effectively in response to COVID-19 vaccination. Learn more
To maximize protection from the Delta variant and prevent possibly spreading it to others, get vaccinated as soon as you can and wear a mask indoors in public if you are in an area of substantial or high transmission.
UPDATE
Given new evidence on the B.1.617.2 (Delta) variant, CDC has updated the guidance for fully vaccinated people. CDC recommends universal indoor masking for all teachers, staff, students, and visitors to K-12 schools, regardless of vaccination status. Children should return to full-time in-person learning in the fall with layered prevention strategies in place.
UPDATE
The White House announced that vaccines will be required for international travelers coming into the United States, with an effective date of November 8, 2021. For purposes of entry into the United States, vaccines accepted will include FDA approved or authorized and WHO Emergency Use Listing vaccines. More information is available here.

Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes

Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes
Updated June 6, 2020

NOT FOR DIAGNOSTIC TESTING USE

Reagents manufactured from these sequences may not be used for diagnostic testing under FDA’s authorization of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel.
Only primers and probes labeled for EUA use and distributed by the International Reagent Resourceexternal icon may be used for diagnostic testing with the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel.

Printer friendly version pdf icon[PDF]

These sequences are intended to be used for the purposes of respiratory virus surveillance and research. The recipient agrees to use them in compliance with all applicable laws and regulations. Every effort has  been made to assure the accuracy of the sequences, but CDC cannot provide any warranty regarding their accuracy.  The recipient can acknowledge the source of sequences in any oral presentations or written publications concerning the research project by referring to the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Should the recipient use these sequences in the design of a diagnostic device, the device developed from these sequences and the use of primers and probes synthesized from these sequences is not authorized under CDC’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel EUA. The device would be considered a new and separate test from the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel and must comply with applicable laws and regulations. CDC has extended an open right of reference to CDC’s EUA for the 2019-nCoV Real-Time RT-PCR Diagnostic Panel. Any recipient seeking FDA authorization for a device based in whole or in part on the design of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel is welcome to reference the CDC EUA (EUA 200001) in their application.

2019-Novel Coronavirus (2019-nCoV) Real-time rRT-PCR Panel Primers and Probes
Name Description Oligonucleotide Sequence (5’>3’) Label1 Final
Conc.
2019-nCoV_N1-F 2019-nCoV_N1 Forward Primer GAC CCC AAA ATC AGC GAA AT None 500nM
2019-nCoV_N1-R 2019-nCoV_N1 Reverse Primer TCT GGT TAC TGC CAG TTG AAT CTG None 500nM
2019-nCoV_N1-P 2019-nCoV_N1 Probe FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1 FAM, BHQ-1 125nM
2019-nCoV_N1-P 2019-nCoV_N1 Probe FAM-ACC CCG CAT /ZEN/ TAC GTT TGG TGG ACC-3IABkFQ FAM, ZEN, 3IABkFQ 125nM
2019-nCoV_N2-F 2019-nCoV_N2 Forward Primer TTA CAA ACA TTG GCC GCA AA None 500nM
2019-nCoV_N2-R 2019-nCoV_N2 Reverse Primer GCG CGA CAT TCC GAA GAA None 500nM
2019-nCoV_N2-P 2019-nCoV_N2 Probe FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1 FAM, BHQ-1 125nM
2019-nCoV_N2-P 2019-nCoV_N2 Probe FAM-ACA ATT TGC /ZEN/ CCC CAG CGC TTC AG-3IABkF FAM, ZEN, 3IABkFQ 125nM
RP-F RNAse P Forward Primer AGA TTT GGA CCT GCG AGC G None 500nM
RP-R RNAse P Reverse Primer GAG CGG CTG TCT CCA CAA GT None 500nM
RP-P RNAse P
Probe
FAM – TTC TGA CCT GAA GGC TCT GCG CG – BHQ-1 FAM, BHQ-1 125nM
RP-P RNAse P
Probe
FAM-TTC TGA CCT /ZEN/ GAA GGC TCT GCG CG-3IABkFQ FAM, ZEN, 3IABkFQ 125nM

1TaqMan® probes are labeled at the 5′-end with the reporter molecule 6-carboxyfluorescein (FAM) and with the quencher, Black Hole Quencher 1 (BHQ-1) (Biosearch Technologies, Inc., Novato, CA) at the 3′-end. TaqMan® probes can also be labeled at the 5′-end with the reporter molecule 6- carboxyfluorescein (FAM) and with a double quencher, ZEN™ Internal Quencher positioned between the ninth (9th) and tenth (10th) nucleotide base in the oligonucleotide sequence and Iowa Black® FQ (3IABkFQ) located at the 3’-end (Integrated DNA Technologies, Coralville, IA).

Note: Oligonucleotide sequences are continually monitored to ensure performance and may be subject to future changes as the SARS-CoV-2 virus evolves.